References
- Tsao CW, Aday AW, Almarzooq ZI, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee., et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93–e621. doi: 10.1161/CIR.0000000000001123.
- Ward C, Ewald E, Koenig K, et al. Prevalence and health care expenditures among Medicare beneficiaries aged 65 years and over with heart conditions. Medicare Current Beneficiary Survey, data highlight. 2017. https://www.cms.gov/Research-Statistics-Data-and-Systems/Research/MCBS/Downloads/HeartConditions_DataBrief_2017.pdf
- Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–237. doi: 10.1038/s41581-019-0244-2.
- Avalere Health. Updated reconciliation package changes drugs eligible for negotiation. 2022. https://avalere.com/insights/updated-reconciliation-package-changes-drugs-eligible-for-negotiation
- Congressional Budget Office. How CBO Estimated the Budgetary Impact of Key Prescription Drug Provisions in the 2022 Reconciliation Act. 2023. https://www.cbo.gov/system/files/2023-02/58850-IRA-Drug-Provs.pdf
- Grabowski H, Long G, Mortimer R, et al. Continuing trends in U.S. brand-name and generic drug competition. J Med Econ. 2021;24(1):908–917. doi: 10.1080/13696998.2021.1952795.
- Grabowski H, DiMasi JA, Long G. Post-Approval innovation for oncology drugs and the Inflation Reduction Act. 2024. Under review; available from the authors.
- ClinicalTrials.gov. Protocol registration data element definitions for interventional and observational studies. 2024. https://clinicaltrials.gov/policy/protocol-definitions
- Berger B, et al. Regulatory approval and expanded market size. NBER Working Paper No. 28889, 2021. https://www.nber.org/system/files/working_papers/w28889/w28889.pdf
- Longo N. Partnership for Health Analytic Research. Implications of the Inflation Reduction Act price setting provisions on post-approval indications for small molecule medicines, 2023. https://www.pharllc.com/wp-content/uploads/2023/05/Implications-of-the-IRA-on-Post-Approval-Small-Molecules-2006-2012_Final.pdf.
- Long N. New government price setting policy threatens post-approval research. (Blog post) November 10, 2022. https://catalyst.phrma.org/new-government-price-setting-policy-threatens-post-approval-research
- Lincoff AM, Brown-Frandsen K, Colhoun HM, SELECT Trial Investigators., et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232. doi: 10.1056/NEJMoa2307563.
- Quantitative Life Sciences. Clinical development success rates and contributing factors, 2011-2020. 2021. https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020